- Home
- INMB vs CNTX Comparison
INMB vs CNTX Comparison
Compare INMB & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- CNTX
- Stock Information
- Founded
- INMB 2015
- CNTX 2015
- Country
- INMB United States
- CNTX United States
- Employees
- INMB N/A
- CNTX N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- INMB Health Care
- CNTX Health Care
- Exchange
- INMB Nasdaq
- CNTX Nasdaq
- Market Cap
- INMB 68.9M
- CNTX 78.0M
- IPO Year
- INMB 2019
- CNTX 2021
- Fundamental
- Price
- INMB $2.91
- CNTX $0.85
- Analyst Decision
- INMB Buy
- CNTX Strong Buy
- Analyst Count
- INMB 4
- CNTX 5
- Target Price
- INMB $9.53
- CNTX $5.50
- AVG Volume (30 Days)
- INMB 4.5M
- CNTX 197.7K
- Earning Date
- INMB 08-04-2025
- CNTX 08-06-2025
- Dividend Yield
- INMB N/A
- CNTX N/A
- EPS Growth
- INMB N/A
- CNTX N/A
- EPS
- INMB N/A
- CNTX N/A
- Revenue
- INMB $50,000.00
- CNTX N/A
- Revenue This Year
- INMB $203.60
- CNTX N/A
- Revenue Next Year
- INMB $13,122.47
- CNTX N/A
- P/E Ratio
- INMB N/A
- CNTX N/A
- Revenue Growth
- INMB N/A
- CNTX N/A
- 52 Week Low
- INMB $1.89
- CNTX $0.49
- 52 Week High
- INMB $11.64
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- INMB 41.06
- CNTX 65.79
- Support Level
- INMB $2.62
- CNTX $0.82
- Resistance Level
- INMB $3.07
- CNTX $1.00
- Average True Range (ATR)
- INMB 0.25
- CNTX 0.07
- MACD
- INMB 0.24
- CNTX 0.01
- Stochastic Oscillator
- INMB 72.26
- CNTX 59.46
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.